PIK3CA and non-small cell lung carcinoma: Oncogenic RET fusions have been demonstrated to activate the kinase domain, leading to uncontrolled activation of the PI3K pathway [54]—again implicating this pathway as a potential key driver of BM in RET fusion-positive NSCLC.